We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+6.63%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$870M
AUM Growth
+$27M
Cap. Flow
+$16.7M
Cap. Flow %
1.92%
Top 10 Hldgs %
32.2%
Holding
103
New
12
Increased
47
Reduced
28
Closed
15

Top Buys

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$16.5M
2
WGS icon
GeneDx Holdings
WGS
+$13.7M
3
DHR icon
Danaher
DHR
+$9.08M
4
DXCM icon
DexCom
DXCM
+$7.49M
5
ASND icon
Ascendis Pharma A/S
ASND
+$6.86M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$27.6M
2
UNH icon
UnitedHealth
UNH
+$26.3M
3
SYK icon
Stryker
SYK
+$10.2M
4
GILD icon
Gilead Sciences
GILD
+$9.29M
5
PODD icon
Insulet
PODD
+$7.14M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVS icon
1
CVS Health
CVS
$122B
$35.7M 4.11%
517,807
+21,071
+4% +$1.38M
PODD icon
2
Insulet
PODD
$9.79B
$33.2M 3.82%
105,762
-24,752
-19% -$7.14M
BSX icon
3
Boston Scientific
BSX
$71.5B
$30.4M 3.5%
283,166
+57,176
+25% +$5.79M
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$29.3B
$30.1M 3.46%
92,338
+23,400
+34% +$6.47M
THC icon
5
Tenet Healthcare
THC
$21.1B
$29.7M 3.42%
168,884
-44,534
-21% -$6.7M
COO icon
6
Cooper Companies
COO
$14.5B
$27.4M 3.15%
385,479
+72,829
+23% +$5.58M
LLY icon
7
Eli Lilly
LLY
$1.06T
$26M 2.98%
33,296
-5,895
-15% -$4.58M
QGEN icon
8
Qiagen
QGEN
$8.72B
$23.9M 2.75%
498,107
+138,463
+39% +$6.02M
ZBH icon
9
Zimmer Biomet
ZBH
$18.4B
$21.9M 2.52%
240,395
+39,895
+20% +$3.86M
DHR icon
10
Danaher
DHR
$144B
$21.7M 2.5%
110,090
+46,840
+74% +$9.08M
NBIX icon
11
Neurocrine Biosciences
NBIX
$16.6B
$20.9M 2.4%
166,010
-2,372
-1% -$272K
SYK icon
12
Stryker
SYK
$130B
$19.9M 2.29%
50,376
-27,314
-35% -$10.2M
DXCM icon
13
DexCom
DXCM
$32B
$19.7M 2.27%
225,875
+95,508
+73% +$7.49M
EW icon
14
Edwards Lifesciences
EW
$51.7B
$19.7M 2.26%
251,741
+50,922
+25% +$3.8M
VRNA
15
DELISTED
Verona Pharma
VRNA
$18.7M 2.15%
197,898
-62,523
-24% -$4.63M
VRDN icon
16
Viridian Therapeutics
VRDN
$2.67B
$18.2M 2.09%
1,298,825
+234,319
+22% +$3.18M
IQV icon
17
IQVIA
IQV
$39.3B
$17.3M 1.98%
+109,500
New +$16.5M
WGS icon
18
GeneDx Holdings
WGS
$2.3B
$16.2M 1.86%
+175,000
New +$13.7M
RVTY icon
19
Revvity
RVTY
$12.8B
$15.2M 1.75%
157,196
+17,639
+13% +$1.66M
GILD icon
20
Gilead Sciences
GILD
$165B
$14.6M 1.68%
131,675
-87,275
-40% -$9.29M
KNSA icon
21
Kiniksa Pharmaceuticals
KNSA
$5.93B
$13.5M 1.55%
488,796
-273,825
-36% -$6.97M
MCK icon
22
McKesson
MCK
$101B
$12.8M 1.47%
17,458
-4,643
-21% -$3.28M
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$12.4B
$12.4M 1.42%
225,150
-52,102
-19% -$3.07M
TVTX icon
24
Travere Therapeutics
TVTX
$5.78B
$12.2M 1.41%
827,060
-127,011
-13% -$2.11M
SDGR icon
25
Schrodinger
SDGR
$1.36B
$11.8M 1.36%
587,556
+106,086
+22% +$2.42M
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Parkman Healthcare Partners held 103 positions worth $870M, up 3.2% from $843M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners's Q2 2025 filing shows 12 new, 47 increased, 28 reduced and 15 closed positions. Its largest new stake was IQVIA: 109,500 shares worth $17.3M. The largest sale was Becton Dickinson, an estimated $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Parkman Healthcare Partners's largest Q2 2025 buy was IQVIA: 109,500 shares worth $17.3M.
  • Parkman Healthcare Partners added most to Danaher in Q2 2025, an estimated $9.08M increase.
  • Parkman Healthcare Partners's biggest Q2 2025 reduction was Stryker, cutting an estimated $10.2M.
  • Parkman Healthcare Partners fully exited Becton Dickinson in Q2 2025, selling an estimated $27.6M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $870M portfolio in Q2 2025.
  • Parkman Healthcare Partners opened 12 new positions and closed 15 in Q2 2025.
  • Parkman Healthcare Partners's portfolio value rose 3.2% quarter-over-quarter to $870M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.